Fatty15 (C15:0 / Pentadecanoic Acid) Research

4 peer-reviewed studies supporting this intervention. Evidence rating: C

4 Studies

0 RCTs

0 Meta-analyses

2020-2024 Year Range

Study Comparison

Study	Year	Type	Journal	Key Finding
Chooi YC et al.	2024	Study	American Journal of Clinical Nutrition	12-week RCT showed C15:0 supplementation combined with Mediterranean diet reduced liver fat by 33% in women with NAFLD, though diet alone achieved similar fat reduction (30%).
Ciesielski V et al.	2024	Study	Biochimie	Comprehensive review established odd-chain fatty acids including C15:0 as important nutrients with unique metabolic roles distinct from even-chain fatty acids.
Venn-Watson SK et al.	2022	Study	PLoS One	C15:0 showed broader and safer cell-based activities than omega-3 EPA across 12 human disease systems
Venn-Watson S et al.	2020	Study	Scientific Reports	Cell-based studies showed C15:0 has dose-dependent beneficial effects on multiple health markers, with efficacy comparable to or exceeding omega-3 fatty acids in some assays.

Study Details

Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial

2024 Study

Chooi YC, Zhang QA, Magkos F, Ng M, et al.

American Journal of Clinical Nutrition

Key Finding: 12-week RCT showed C15:0 supplementation combined with Mediterranean diet reduced liver fat by 33% in women with NAFLD, though diet alone achieved similar fat reduction (30%).

View Summary

Double-blinded RCT examining effects of pentadecanoic acid (C15:0) supplementation combined with an Asian-adapted Mediterranean diet on NAFLD in 88 Chinese women.

Both diet groups lost more weight and liver fat than controls, but C15:0 supplementation showed only modest additional benefits over diet alone, primarily in LDL cholesterol reduction.

Full Details View Source ↗

New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review

2024 Study

Ciesielski V, Legrand P, Blat S, Rioux V

Biochimie

Key Finding: Comprehensive review established odd-chain fatty acids including C15:0 as important nutrients with unique metabolic roles distinct from even-chain fatty acids.

View Summary

Authoritative review on the biology and health effects of odd-chain saturated fatty acids, including pentadecanoic acid (C15:0).

Full Details View Source ↗

Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems

2022 Study

Venn-Watson SK, Butterworth CN

PLoS One

Key Finding: C15:0 showed broader and safer cell-based activities than omega-3 EPA across 12 human disease systems

View Summary

Study comparing the cell-based activities of pentadecanoic acid (C15:0) to eicosapentaenoic acid (EPA/omega-3) across multiple human disease systems.

Full Details View Source ↗

Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans

2020 Study

Venn-Watson S, Lumpkin R, Dennis EA

Scientific Reports

Key Finding: Cell-based studies showed C15:0 has dose-dependent beneficial effects on multiple health markers, with efficacy comparable to or exceeding omega-3 fatty acids in some assays.

View Summary

Study comparing the cellular effects of pentadecanoic acid (C15:0) to omega-3 fatty acids across multiple health-relevant assays.

Full Details View Source ↗

Evidence Assessment

C Limited Evidence

This intervention has preliminary evidence from early-stage research, mechanistic studies, or observational data. More rigorous trials are needed.

← Back to Fatty15 (C15:0 / Pentadecanoic Acid)